COVID-19 Vaccinology Update: Will New Variants Necessitate New Vaccines?
IKEEP. Neelika Malavige & Shabir A. Madhi . 03/05/21; 315478
  Neelika Malavige & Shabir A. Madhi
Neelika Malavige & Shabir A. Madhi
Contributions Biography
About this activity
Vaccinology Outline – March 2021
The emergence and spread of COVID-19 variants raises new questions and scientists must debate whether the variants undercut the effectiveness of first-generation COVID-19 vaccines. The new strains of  SARS-CoV-2, first identified in the United Kingdom (B.1.1.7), Brazil (P.1) and South Africa (B.1.351), have developed a substantial number of mutations, especially in the S-protein, that seem to reduce the effects of antibodies crucial to fending off infection. This webinar is a follow up to ISID’s webinar on “COVID-19 Vaccinology Update: Development, Use and Effect on Public Health” released in January 2021. Prof. Malavige and Prof. Madhi will discuss the implications of these mutations on vaccine response and how vaccine manufacturers plan to update their vaccines to better target the emerging variants. Additionally, Prof. Madhi will discuss new results from phase 3 trials and what it will take to achieve herd immunity. 

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies